Cargando…

Characteristics of Elderly Patients Initiating Sitagliptin or Non-DPP-4-Inhibitor Oral Antihyperglycemic Agents: Analysis of a Cross-Sectional US Claims Database

INTRODUCTION: Previous analyses concluded that patients initiating treatment with sitagliptin are older and have more comorbidities than patients initiating treatment with other oral antihyperglycemic agents (OAHAs). However, these studies focused on the general population or subjects ≤ 65 years of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Tongtong, McNeill, Ann Marie, Chen, Yong, O’Neill, Edward A., Engel, Samuel S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801246/ https://www.ncbi.nlm.nih.gov/pubmed/29330813 http://dx.doi.org/10.1007/s13300-017-0360-6

Ejemplares similares

Randomized clinical trial comparing the efficacy and safety of treatment with the once‐weekly dipeptidyl peptidase‐4 (DPP‐4) inhibitor omarigliptin or the once‐daily DPP‐4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy
por: Goldenberg, Ronald, et al.
Publicado: (2017)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahrén, Bo
Publicado: (2010)

Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co‐transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases
por: Wang, Lu, et al.
Publicado: (2019)

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin
por: Kaku, Kohei, et al.
Publicado: (2021)

Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People ≥ 65 Years Old with Type 2 Diabetes and Mild Renal Insufficiency
por: Raji, Annaswamy, et al.
Publicado: (2020)

A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control
por: Gantz, Ira, et al.
Publicado: (2017)

Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials
por: Ommen, Elizabeth S., et al.
Publicado: (2015)

Efficacy and Safety of Sitagliptin in Hispanic/Latino Patients with Type 2 Diabetes: A Pooled Analysis from Ten Randomized, Placebo-Controlled Phase 3 Clinical Trials
por: Raji, Annaswamy, et al.
Publicado: (2018)

Erratum to: Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials
por: Ommen, Elizabeth S., et al.
Publicado: (2015)

Characterization of Sitagliptin Use in Patients with Type 2 Diabetes and Chronic Kidney Disease by Cross-Sectional Analysis of a Medical Insurance Claims Database
por: Brodovicz, Kimberly G., et al.
Publicado: (2015)

Novel hit of DPP-4Is as promising antihyperglycemic agents with dual antioxidant/anti-inflammatory effects for type 2 diabetes with/without COVID-19
por: Mahgoub, Shahenda, et al.
Publicado: (2022)

Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes
por: Koyani, Chintan N., et al.
Publicado: (2018)

Antihyperglycemic Medications: A Claims-Based Estimate of First-line Therapy Use Prior to Initialization of Second-line Medications
por: Tseng, Yi-Ju, et al.
Publicado: (2017)

Health Care Database Comparisons by State
por: McNeill, Matt
Publicado: (2022)

Tropical Plant Extracts as Potential Antihyperglycemic Agents
por: Manaharan, Thamilvaani, et al.
Publicado: (2012)

A randomized, placebo‐controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin
por: Seino, Yutaka, et al.
Publicado: (2021)

Double‐blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT‐M study
por: Frias, Juan P., et al.
Publicado: (2019)

A randomized, placebo‐ and sitagliptin‐controlled trial of the safety and efficacy of omarigliptin, a once‐weekly dipeptidyl peptidase‐4 inhibitor, in Japanese patients with type 2 diabetes
por: Gantz, Ira, et al.
Publicado: (2017)

Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co‐administered to Chinese patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2016)

A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus
por: Gantz, Ira, et al.
Publicado: (2017)

A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT‐R study
por: Scott, Russell, et al.
Publicado: (2018)

Pleiotropic effects of sitagliptin versus voglibose in patients with type 2 diabetes inadequately controlled via diet and/or a single oral antihyperglycemic agent: a multicenter, randomized trial
por: Matsushima, Yukiko, et al.
Publicado: (2016)

Sitagliptin, a DPP-4 Inhibitor, Acutely Inhibits Intestinal Lipoprotein Particle Secretion in Healthy Humans
por: Xiao, Changting, et al.
Publicado: (2014)

A randomised, double‐blind, trial of the safety and efficacy of omarigliptin (a once‐weekly DPP‐4 inhibitor) in subjects with type 2 diabetes and renal impairment
por: Chacra, Antonio, et al.
Publicado: (2017)

A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice
por: Berger, Joel P., et al.
Publicado: (2017)

Effects of the Antidiabetic Drugs Evogliptin and Sitagliptin on the Immune Function of CD26/DPP4 in Th1 Cells
por: Yoon, Hyunyee, et al.
Publicado: (2021)

Double‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT‐I Study
por: Roussel, Ronan, et al.
Publicado: (2018)

Proximal Predictors of Long-Term Discontinuance with Noninsulin Antihyperglycemic Agents
por: Stuart, Bruce C., et al.
Publicado: (2016)

Real-World Characterization of Women with Diagnosed Endometriosis Initiating Therapy with Elagolix Using a US Claims Database
por: Surrey, Eric S, et al.
Publicado: (2020)

DPP4 Inhibitor Sitagliptin Enhances Lymphocyte Recruitment and Prolongs Survival in a Syngeneic Ovarian Cancer Mouse Model
por: Wilson, Amy L., et al.
Publicado: (2021)

Identification of DPP4/CTNNB1/MET as a Theranostic Signature of Thyroid Cancer and Evaluation of the Therapeutic Potential of Sitagliptin
por: Cheng, Sheng-Yao, et al.
Publicado: (2022)

Amla as an antihyperglycemic and hepato-renal protective agent in fluoride induced toxicity
por: Vasant, Rupal A., et al.
Publicado: (2012)

Design, Synthesis and in Vivo Evaluation of Novel Glycosylated Sulfonylureas as Antihyperglycemic Agents
por: Suaifan, Ghadeer A. R. Y., et al.
Publicado: (2015)

A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin
por: Lee, Seung-Hwan, et al.
Publicado: (2017)

Abundant Human DNA Contamination Identified in Non-Primate Genome Databases
por: Longo, Mark S., et al.
Publicado: (2011)

The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms
por: Zeng, Yanmei, et al.
Publicado: (2014)

A Physiologically‐Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP‐1 and GIP and the DPP4 Inhibitor Sitagliptin
por: Balazki, Pavel, et al.
Publicado: (2020)

The durability of sitagliptin in elderly patients with type 2 diabetes
por: Hsieh, Ching-Jung, et al.
Publicado: (2014)

Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database
por: Viscidi, Emma, et al.
Publicado: (2021)

Metabolic effects of antihyperglycemic agents and mortality: meta-analysis of randomized controlled trials
por: Rados, Dimitris Varvaki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8sj0vkda8jgh1dupaf5lvl7kop